Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.39 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.39 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.39 |
| ▸ | ABL1 | P00519 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16636863 | 0.85 | IL2 (0.39) | ABCB1ABCC1CSNK1DCSNK1EKDM4E | |
| SCHEMBL16636428 | 0.84 | IL2 (0.45) | KDM4ENPC1PKMRAB9A | |
| SCHEMBL16636510 | 0.83 | IL2 (0.37) | CSNK1DCSNK1EKDM4ENPC1PKM | |
| SCHEMBL16636887 | 0.83 | NPC1 (0.37) | ABCB1KDM4ENPC1PKMRAB9A | |
| SCHEMBL16637371 | 0.82 | IL2 (0.43) | ABL1KDM4ENPC1PKMRAB9A | |
| SCHEMBL16636702 | 0.81 | MAOB (0.38) | KDM4ENPC1RAB9A | |
| SCHEMBL16636859 | 0.74 | HTR1F (0.38) | ABCB1ABCC1CSNK1DCSNK1EABL1 | |
| SCHEMBL16636909 | 0.73 | IL2 (0.42) | KDM4ENPC1PKMRAB9AF10 | |
| SCHEMBL16636744 | 0.73 | IL2 (0.48) | — | |
| SCHEMBL16636701 | 0.73 | IL2 (0.42) | KDM4ENPC1RAB9AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9611263-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-08-11 | — | — | US | disclosed |
| WO-2015054283-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229845-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | ABCB1 1679/4885ABCC1 1380/4885CSNK1D 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.